Press Releases

January 20, 2015  |  Aduro Biotech reports long-term survival and immune biomarker data from Phase 2 clinical trial of its immuno-oncology regimen in patients with pancreatic cancer

January 12, 2015  |  Aduro Biotech announces Phase 2 clinical trial results for pancreatic cancer combination immunotherapy published in Journal of Clinical Oncology

January 05, 2015  |  Aduro Biotech closes $51.4 million Series D financing

December 03, 2014  |  Aduro Biotech announces preclinical data presented at American Association for Cancer Research Tumor Immunology and Immunotherapy Conference

October 23, 2014  |  Aduro presents updated interim results from Phase 1b clinical trial in mesothelioma at International Mesothelioma Interest Group Conference

October 16, 2014  |  Aduro expands collaboration with Johnson & Johnson Innovation and Janssen for lung cancer immunotherapies

October 15, 2014  |  Aduro BioTech announces interim Phase 1B clinical data of CRS-207 for the treatment of mesothelioma accepted for oral presentation at the International Mesothelioma Interest Group conference


Events & Presentations

Stephen Isaacs interviewed about Aduro's mesothelioma program
September 10, 2014  |  The Meso Foundation

Aduro announces pancreatic cancer and mesothelioma abstracts to be presented at 2014 ASCO annual meeting
May 20, 2014  |  Business Wire

Dirk Brockstedt presents at the 11th Annual International Symposium on Malignant Mesothelioma (first presentation on video, ends at 15:45)
March 07, 2014  |  Mesothelioma Applied Research Foundation



Immunotherapy Duo Improves Survival in Metastatic Pancreatic Cancer
February 20, 2014  |  The ASCO Post